Kellett Wealth Advisors LLC Buys 70 Shares of Eli Lilly and Company (NYSE:LLY)

Kellett Wealth Advisors LLC raised its position in Eli Lilly and Company (NYSE:LLY) by 5.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,371 shares of the company’s stock after acquiring an additional 70 shares during the quarter. Eli Lilly and Company makes up 0.6% of Kellett Wealth Advisors LLC’s investment portfolio, making the stock its 29th largest position. Kellett Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $799,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Fairfield Bush & CO. bought a new stake in Eli Lilly and Company during the first quarter worth about $107,000. Roundview Capital LLC raised its holdings in shares of Eli Lilly and Company by 2.6% during the first quarter. Roundview Capital LLC now owns 2,056 shares of the company’s stock valued at $589,000 after purchasing an additional 53 shares during the last quarter. Merit Financial Group LLC purchased a new position in shares of Eli Lilly and Company during the first quarter valued at approximately $210,000. NewEdge Advisors LLC grew its stake in Eli Lilly and Company by 9.9% during the first quarter. NewEdge Advisors LLC now owns 53,052 shares of the company’s stock valued at $15,193,000 after acquiring an additional 4,774 shares in the last quarter. Finally, Barometer Capital Management Inc. purchased a new position in Eli Lilly and Company during the first quarter valued at $561,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of NYSE LLY traded down $4.82 during mid-day trading on Thursday, reaching $745.95. The company’s stock had a trading volume of 1,701,145 shares, compared to its average volume of 3,067,708. The stock has a 50-day moving average of $764.03 and a two-hundred day moving average of $657.67. The stock has a market capitalization of $708.77 billion, a P/E ratio of 129.32, a P/E/G ratio of 1.63 and a beta of 0.34. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94. Eli Lilly and Company has a 1-year low of $367.35 and a 1-year high of $800.78.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The business had revenue of $9.35 billion during the quarter, compared to analysts’ expectations of $8.95 billion. During the same period in the prior year, the business earned $2.09 earnings per share. The company’s quarterly revenue was up 28.1% compared to the same quarter last year. On average, equities research analysts anticipate that Eli Lilly and Company will post 12.52 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have commented on LLY. Bank of America lifted their price objective on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. The Goldman Sachs Group lifted their price target on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a research note on Thursday, April 11th. Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. Citigroup lifted their price target on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a research note on Tuesday, April 2nd. Finally, BMO Capital Markets lifted their price objective on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the company an “outperform” rating in a report on Wednesday, February 7th. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $728.05.

Insider Activity at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 54,032 shares of the company’s stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $645.07, for a total value of $34,854,422.24. Following the completion of the sale, the insider now owns 99,488,598 shares of the company’s stock, valued at $64,177,109,911.86. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.13% of the stock is currently owned by insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.